cntx-20260805 0001842952 FALSE 0001842952 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2026 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2001 Market Street, Suite 3915 , Unit #15 Philadelphia , Pennsylvania 19103 (Address of principal executive offices including zip code) (267) 225-7416 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01. Regulation FD Disclosure. On August 5, 2026, Context Therapeutics Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01. Financial Statements and Exhibits. ( d) Exhibits Exhibit No. Description 99.1 Context Therapeutics Inc. Corporate Presentation — August 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 5, 2026 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

Context Therapeutics Inc. updated its corporate presentation on August 5, 2026 for use in investor and analyst meetings. This routine disclosure demonstrates the company's commitment to stakeholder communication and transparency regarding its strategic direction.

On August 5, 2026, Context Therapeutics Inc. updated its corporate presentation intended for use in meetings with investors and analysts. This update includes various strategic insights and financial information that the company aims to communicate to its stakeholders. The presentation is filed as Exhibit 99.1 with the current report and is relevant for understanding the corporate direction and investment opportunities. This action may influence investor perceptions and is part of the company's efforts to maintain transparency and engagement with its financial community.

Context Therapeutics Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means